Correlative factors of paclitaxel hypersensitivity in cervical cancer chemotherapy

VernacularTitle:宫颈癌患者紫杉醇化疗过敏的相关因素分析
Author: Xiaofang ZHOU ; Linya CHEN ; Yefang WU
Publication Type:Journal Article
Keywords: Cervix neoplasms; Paclitaxel; Anaphylaxis; Risk factors
From: Chinese Journal of Primary Medicine and Pharmacy 2016;23(13):1939-1941,1942
CountryChina
Language:Chinese
Abstract: Objective To investigate related factors of hypersensitivity reactions in patients undergoing paclitaxel chemotherapy for cervical cancer and provide measures for prevention of the side effects.Methods A ret-rospective survey was taken to analyze the clinical data from 186 cervical cancer patients who accepted paclitaxel chemotherapy from January 2013 to December 2014.SPSS 17.0 was used for single factor analysis and multi -factor logistic regression analysis.Results Among the 186 cervical cancer patients enrolled in this study,34 cases occurred hypersensitivity reactions.The incidence rate of anaphylaxis was 18.3%.Both eosinophil count of more than 0.2 × 109 /L(χ2 =4.171,P <0.05)and history of drug allergy(χ2 =10.667,P <0.01)were not merely risk factors of anaphylaxis,but also independent risk factors(OR =4.691,2.257,all P <0.01 ).Conclusion The incidence of hypersensitivity after paclitaxel chemotherapy in cervical cancer patients is high.Eosinophil count ≥ 0.2 ×109 /L before chemotherapy and history of drug allergy are not merely risk factors of anaphylaxis,but also independent risk factors,which require more attention.